Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028983 | 1.00 | HRH3 (0.32) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL2031312 | 1.00 | HRH3 (0.32) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL2033338 | 0.90 | HRH3 (0.31) | HRH3MAPK1 | |
| SCHEMBL1765120 | 0.79 | KMT2A (0.38) | CHRM2CHRM3 | |
| SCHEMBL1764799 | 0.79 | KMT2A (0.38) | CHRM2CHRM3 | |
| SCHEMBL25684409 | 0.72 | MAPK1 (0.37) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL7359958 | 0.71 | MAPK1 (0.36) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL7379626 | 0.71 | MAPK1 (0.36) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL22152561 | 0.71 | MAPK1 (0.36) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL9352527 | 0.70 | CYP2D6 (0.40) | HRH3MAPK1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | HRH3 4251/4885MAPK1 1975/4885CHRM2 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.